Signed between an agency, institute and three pharmaceutical companies, the initiative aims to develop the country’s pharma manufacturing sector by transforming its manufacturing operations and technologies. The Ministry for Trade and Industry also encourages manufacturing in the country.
Singapore – A Memorandum of Understanding (MoU) was recently signed between the Agency for Science, Technology and Research (A*Star), the National University of Singapore (NUS) and three pharmaceutical companies – GSK, Pfizer and MSD to kick start the launch of the Pharma Innovation Programme Singapore (PIPS) initiative. The initiative is aimed to develop the country’s pharma manufacturing sector by transforming its manufacturing operations and technologies.
This includes enabling green and sustainable manufacturing through the use of bio-catalysis technologies, as well as developing a fully-automated supply chain that can predict and react to patient demands and market trends.
The Minister for Trade and Industry S Iswaran who was the Guest of Honour at the Future of Manufacturing Summit where the MOU was signed addressed the gathering. He said, “It is important to strengthen partnerships within the local manufacturing sector to pool resources. PIPS combines the research capabilities of the public sector with the expertise of private pharma companies.”
Iswaran also stated that manufacturing is a key pillar of Singapore’s economy and that the Government is committed to support the development of advanced manufacturing technologies to ensure that Singapore’s manufacturing sector remains competitive.